Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers

Cancer and Metastasis Reviews

Volumn 18, Issue 4, 1999, Pages 483-490

  Gong, Michael C ^a,c   Chang, Sam S ^a   Sadelain, Michel ^a   Bander, Neil H ^b   Heston, Warren D W ^a  

^a Mem Sloan Kettering Cancer C ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiogenesis; Gene therapy; Immunotherapy; Monoclonal antibody

Indexed keywords

MONOCLONAL ANTIBODY; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TISSUE DISTRIBUTION;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARBOXYPEPTIDASES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASMS; PROSTATIC NEOPLASMS;

EID: 0033511652     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006308826967     Document Type: Article

References (35)

1. 1. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7: 927-35, 1987
2. 2. Israeli RS, Powell CT, Fair WR, Heston WD: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 53: 227-30, 1993
3. 3. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD: Expression of the prostate-specific membrane antigen. Cancer Res 54: 1807-11, 1994
4. 4. Rinker-Schaeffer CW, Hawkins AL, Su SL, Israeli RS, Griffin CA, Isaacs JT, Heston WD: Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11. Genomics 30: 105-8, 1995
5. 5. Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, Cross J, Whelan P, MacLennan KA, Meredith DM, Markham AF: Prostate-specific membrane antigen: evidence for the existence of a second related human gene. Br J Cancer 72: 583-8, 1995
6. 6. O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, Zandvliet D, Russell PJ, Molloy PL, Nowak NJ, Shows TB, Mullins C, Vonder Haar RA, Fair WR, Heston WD: Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1443: 113-27, 1998
7. 7. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WD: Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2: 1445-51, 1996
8. 8. Carter RE, Feldman AR, Coyle JT: Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 93: 749-53, 1996
9. 9. Luthi-Carter R, Barczak AK, Speno H, Coyle JT: Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 286: 1020-5, 1998
10. 10. Barrett AJ: Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB). Enzyme Nomenclature. Recommendations 1992. Suppl 4: corrections and additions (1997). Eur J Biochem 250: 1-6, 1997
11. 11. Troyer JK, Feng Q, Beckett WGL: Biochemical characterization and mapping of the 7E11-CS.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1: 29-37, 1995
12. 12. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57: 3629-34, 1997
13. 13. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL: Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res 58: 4787-9, 1998
14. 14. Murphy GP, Greene TG, Tino WT, Boynton AL, Holmes EH: Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J Urol 160: 2396-401, 1998
15. 15. Wright GL, Haley C, Beckett ML, Schellhammer PF: Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissue. Urol Oncol 1: 18-28, 1995
16. 16. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82: 2256-61, 1998
17. 17. Sweat SD, Pacelli, A, Murphy GP, Bostwick DG: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52: 637-40, 1998
18. 18. Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48: 326-34, 1996
19. 19. Kawakami M, Nakayama J: Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 57: 2321-4, 1997
20. 20. Chang SS, Reuter VE, Heston WD, Hutchinson B, Grauer LS, Gaudin PB: Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. Cancer 88: 407-15, 2000
21. 21. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer 62: 552-8, 1995
22. 22. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 59: 3192-8, 1999
23. 23. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB: Prostate-specific membrane antigen (PSMA) is produced in tumor-associated neovasculature. Clin Cancer Res, 1999 (in press)
24. 24. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3: 81-5, 1997
25. 25. Elgamal AA, Troychak MJ, Murphy GP: ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate 37: 261-9, 1998
26. 26. Petronis JD, Regan F, Lin K: Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. Clin Nucl Med 23: 672-7, 1998
27. 27. Kahn D, Williams RD, Manyak MJ, Haseman MK, Seldin DW, Libertino JA, Maguire RT: 111 Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group. J Urol 159: 2041-6, 1998
28. 28. Kahn D, Williams RD, Seldin DW, Libertino JA, Hirschhorn M, Dreicer R, Weiner GJ, Bushnell D, Gulfo J: Radioimmunoscintigraphy with 111 indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 152: 1490-5, 1994
29. 29. Michaels EK, Blend M, Quintana JC: 111 Indium-capromab pendetide unexpectedly localizes to renal cell carcinoma. J Urol 161: 597-8, 1999
30. 30. Israeli RS, Miller WH, Su SL, Powell CT, Fair WR, Samadi DS, Huryk RF, DeBlasio A, Edwards ET, Wise GJ, Heston WDW: Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res 54: 6306-10, 1994
31. 31. Zhang Y, Zippe CD, Van Lente F, Klein EA, Gupta MK: Combined nested reverse transcription-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in detecting circulating prostatic cells. Clin Cancer Res 3:1215-20, 1997
32. 32. Ghossein RA, Osman I, Bhattacharya S, Ferrara J, Fazzari M, Cordon-Cardo C, Scher HI: Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction. Diagn Mol Pathol 8: 59-65, 1999
33. 33. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 58: 4055-60, 1998
34. 34. Eshhar Z, Bach N, Fitzer-Attas CJ, Gross G, Lustgarten J, Waks T, Schindler DG: The T-body approach: potential for cancer immunotherapy. Springer Semin Immunopathol 18: 199-209, 1996
35. 35. Gong MC, Latouche JB, Krause A, Heston DWD, Bander NH, Sadelain M: Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1: 123-127, 1999